Molcure is a biopharmaceutical company whose passionate associates are dedicated to the discovery of antibody drugs and improving the lives of patients.
Abtracer is a patent pending, rapid antibody engineering system which combines the Phage Display technique and next generation sequencing. We can design antibody DNA sequences with high-affinity and high-specificity by modifying the conventional framework and using a machine learning algorithm to analyze sequencing data.
|Corporate Name||Molcure Inc|
|Head Office||1-12-11 Taito, Taito, Tokyo 110-0016 JAPAN|
|Executives||Yutaro Kyono, Yoichiro Hara, Eli Lyons|
He is teaching “Molecular biology” and “Genome analysis programming” at Keio University. His major is Bioinformatics.
After graduated from Tokyo University of Pharmacy and Life Sciences, now he is a master student of Keio university, and his major is ubiquitous computing.
1-12-11 Taito, Taito, Tokyo 110-0016
Abtracer is a patent-pending advanced method combining the phage display technique and next generation sequencing. By using the Display-seq (DP-Seq) method and advanced bioinformatics techniques, our innovative antibody discovery service can comprehensively acquire a high affinity and specific antibody sequence.
Ph.D. candidate in the Dept. of Medical Genome Sciences, Graduate School of Frontier Sciences at Univ. of Tokyo.
He majored in developmental biology at Meiji University. Also he has founded two company before Molcure.
The SmartLabModule™(SLM) can decrease the cost of each experiment while simultaneously increasing the through-put. Web-based software, SLM Conductor, wirelessly controls all SLMs, scheduling tasks and managing experimental flow.
Potential merits created by increase of lead antibody variation.
Rapid design of high quality and high diversity lead antibody candidates